Common use of ABOUT THIS PROSPECTUS SUPPLEMENT Clause in Contracts

ABOUT THIS PROSPECTUS SUPPLEMENT. This document consists of two parts. The first part is this prospectus supplement, which describes the specific terms of this offering. The second part is the accompanying prospectus, which is part of a registration statement that we filed with the SEC using a “shelf” registration process. The accompanying prospectus describes more general information, some of which may not apply to this offering. Under this shelf registration process, we may from time to time sell our common shares having an aggregate offering price of up to $50,000,000 under this prospectus supplement at prices and on terms to be determined by market conditions at the time of the offering. Before buying any of the common shares that we are offering, we urge you to carefully read both this prospectus supplement and the accompanying prospectus together with all of the information incorporated by reference herein, as well as the additional information described under the headings “Where You Can Find More Information” and “Incorporation by Reference.” These documents contain important information that you should consider when making your investment decision. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in any document incorporated by reference in this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement, provided that if any statement in one of these documents is inconsistent with a statement in another document having a later date —for example, a document incorporated by reference in this prospectus supplement—the statement in the document having the later date modifies or supersedes the earlier statement. We have not authorized anyone to provide any information other than that contained in or incorporated by reference in this prospectus and any related free writing prospectus filed by us with the SEC. We have not, and SVB Leerink has not, authorized anyone to provide you with different information. We take no responsibility for, and can provide no assurance as to the reliability of any other information that others may give you. This prospectus supplement does not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in this prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus supplement, the documents incorporated by reference and any related free writing prospectus is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed materially since those dates. You should also read and consider the information in the documents to which we have referred you in the sections entitled “Where You Can Find More Information” and “Incorporation by Reference” in this prospectus supplement. Unless otherwise indicated or the context otherwise requires, all references in this prospectus supplement to “InflaRx N.V.,” “InflaRx,” the “Company,” “we,” “our,” “ours,” “us” or similar terms refer to InflaRx N.V. and its subsidiaries.

ABOUT THIS PROSPECTUS SUPPLEMENT. This document consists of two parts. The first part is this prospectus supplement, which describes the specific terms of this offering. The second part is supplement and the accompanying prospectus, which is base prospectus are part of a registration statement on Form F-3 (Registration No. 333-251304) that we filed with the SEC Securities and Exchange Commission ("SEC”) using a “"shelf” registration process. Under this "shelf” registration process, we may, from time to time, sell or issue any of the combination of securities described in the accompanying base prospectus in one or more offerings with a maximum aggregate offering price of up to US $80,000,000. The accompanying base prospectus describes more provides you with a general informationdescription of us and the securities we may offer, some of which may do not apply to this offering. Under this shelf registration processEach time we sell securities, we may from time to time sell our common shares having an aggregate offering price of up to $50,000,000 under this provide a prospectus supplement at prices and on that contains specific information about the terms to be determined by market conditions at the time of the that offering. Before buying any of the common shares that we are offering, we urge you to carefully read both this A prospectus supplement and may also add, update, or change information contained in the accompanying base prospectus. This prospectus together with all supplement relates to the offering of the information incorporated by reference herein, as well as the additional information described under the headings “Where You Can Find More Information” and “Incorporation by Reference.” These documents contain important information that you should consider when making your investment decisionour Ordinary Shares. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, supplement and the information contained in the accompanying prospectus or in any document incorporated by reference in this prospectus supplement, on the other handbase prospectus, you should rely on the information in this prospectus supplement. This prospectus supplement, provided that if any statement in one of these the accompanying base prospectus, and the documents is inconsistent with a statement in another document having a later date —for example, a document incorporated we incorporate by reference in herein and therein include important information about us and our Ordinary Shares and other information you should know before investing. You should read both this prospectus supplement—supplement and the statement in accompanying base prospectus, together with the document having additional information described below under the later date modifies or supersedes heading "Where You Can Find Additional Information.” You should rely only on the earlier statement. We have not authorized anyone to provide any information other than that contained in or incorporated by reference in this prospectus supplement, the accompanying base prospectus, and any related free writing prospectus filed prepared by or on behalf of us with the SECor to which we have referred you. We have not, and SVB Leerink AGP has not, authorized anyone to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We take no responsibility forare not, and can provide no assurance as to the reliability of any other information that others may give you. This prospectus supplement does not constitute AGP is not, making an offer to sell or the solicitation of an offer to buy any securities other than the securities described in this prospectus supplement or an offer to sell or the solicitation of an offer to buy such these securities in any circumstances jurisdiction where the offer or sale is not permitted or in which such the person making that offer or solicitation is unlawfulnot qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. You should assume that the information appearing in this prospectus supplement, the accompanying base prospectus, and the documents incorporated by reference herein and any related free writing prospectus therein is accurate only as of their the date of those respective datesdocuments. Our business, financial condition, results of operations and prospects may have changed materially since those dates. You should also carefully read this entire prospectus supplement and consider the accompanying base prospectus, including the information included and referred to under "Risk Factors” below, the information incorporated by reference in this prospectus supplement and in the accompanying base prospectus, and the financial statements and the other information incorporated by reference in the accompanying base prospectus, before making an investment decision. Unless otherwise stated in this prospectus supplement, "we,” "us,” "our,” or "our company,” refers to VivoPower International PLC, our subsidiaries, and our predecessor operations. NOTEON FORWARD-LOOKING STATEMENTS The statements contained in this prospectus supplement and accompanying prospectus and the documents incorporated by reference herein include forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Words such as, but not limited to, "believe,” "expect,” "anticipate,” "estimate,” "intend,” "may,” "plan,” "potential,” "predict,” "project,” "targets,” "likely,” "will,” "would,” "could,” "should,” "continue,” and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Although we believe that we have a reasonable basis for each forward-looking statement contained in this prospectus supplement and incorporated by reference in the prospectus, we caution you that these statements are based on our projections of the future that are subject to known and unknown risks and uncertainties and other factors that may cause our actual results, level of activity, performance or achievements expressed or implied by these forward-looking statements, to differ. The sections in our periodic reports, including our Annual Report on Form 20-F for the fiscal year ended June 30, 2021, titled "Business,” "Risk Factors,” and "Operating and Financial Review and Prospects,” as well as other sections in this prospectus supplement and accompany prospectus and the documents or reports incorporated by reference in the prospectus, discuss some of the factors that could contribute to these differences. These forward-looking statements include, among other things, statements about: ● our expectations regarding our revenue, expenses and other results of operations; ● our plans to acquire, invest in, develop or sell our investments in energy projects or joint ventures, including in the electric vehicle sector; ● our ability to attract and retain customers; ● the growth rates of the markets in which we compete; ● our liquidity and working capital requirements; ● our ability to raise sufficient capital to realize development opportunities and thereby generate revenue; ● our anticipated strategies for growth; ● our ability to anticipate market needs and develop new and enhanced solutions to meet those needs; ● anticipated trends and challenges in our business and in the markets in which we operate; ● our expectations regarding demand for solar power by energy users or investor in projects; ● our expectations regarding changes in the cost of developing and constructing solar projects; ● our ability to compete in our industry and innovation by our competitors; ● the extent to which the COVID-19 pandemic affects our business, financial condition and results of operations; ● our expectations regarding our ongoing legal proceedings; ● our ability to adequately protect our intellectual property; and ● our plans to pursue strategic acquisitions. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important cautionary statements in this prospectus supplement, the accompanying prospectus or in the documents to which we have referred you incorporated by reference in the sections entitled “Where You Can Find More Informationprospectus, particularly in the "Risk Factors” and “Incorporation by Referencesection, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. For a summary of such factors, please refer to the section titled "Risk Factors” in this prospectus supplement, the accompanying prospectus, as updated and supplemented by the discussion of risks and uncertainties under "Risk Factors” contained in our most recent Annual Report on Form 20-F, as revised or supplemented by our subsequent periodic reports filed under the Exchange Act, as well as any amendments thereto, as filed with the SEC and which are incorporated by reference. Unless otherwise indicated The information contained in this document is believed to be current as of the date of this document. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law. In light of these assumptions, risks and uncertainties, the context otherwise requires, all references results and events discussed in the forward-looking statements contained in this prospectus supplement or in any document incorporated herein by reference might not occur. Investors are cautioned not to “InflaRx N.V.,” “InflaRx,” place undue reliance on the “Company,” “we,” “our,” “ours,” “us” forward-looking statements, which speak only as of the date of this prospectus or similar terms refer the date of the document incorporated by reference. We are not under any obligation, and we expressly disclaim any obligation, to InflaRx N.V. and its subsidiariesupdate or alter any forward- looking statements, whether as a result of new information, future events or otherwise. All subsequent forward-looking statements attributable to us or to any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.

ABOUT THIS PROSPECTUS SUPPLEMENT. This document consists of two parts. The first part is this prospectus supplement, which describes the specific terms of this offering. The second part is supplement and the accompanying prospectus, which is base prospectus are part of a registration statement on Form S-3 (File No. 333-199446) that we filed with the SEC using Securities and Exchange Commission ("SEC") utilizing a “"shelf” " registration process. Each time we sell securities under the accompanying base prospectus we will provide a prospectus supplement that will contain specific information about the terms of that offering, including the price, the amount of securities being offered and the plan of distribution. The shelf registration statement was initially filed with the SEC on October 17, 2014, and was declared effective by the SEC on September 2, 2016. This prospectus supplement describes the specific details regarding this offering and may add, update or change information contained in the accompanying base prospectus. The accompanying base prospectus describes more provides general informationinformation about us, some of which which, such as the section entitled "Plan of Distribution," may not apply to this offering. Under Generally, when we refer to this shelf registration process, "prospectus," we may from time are referring to time sell our common shares having an aggregate offering price of up to $50,000,000 under both documents combined. If information in this prospectus supplement at prices is inconsistent with the accompanying base prospectus or the information incorporated by reference, you should rely on this prospectus supplement. This prospectus supplement, together with the accompanying base prospectus and on terms to be determined the documents incorporated by market conditions at the time of the offering. Before buying any of the common shares that we are offering, we urge you to carefully read both reference into this prospectus supplement and the accompanying base prospectus together with and any related free writing prospectus, includes all of the material information incorporated by reference herein, as well as the additional information described under the headings “Where You Can Find More Information” and “Incorporation by Reference.” These documents contain important information that you should consider when making your investment decision. To the extent there is a conflict between the information contained in relating to this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in any document incorporated by reference in this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement, provided that if any statement in one of these documents is inconsistent with a statement in another document having a later date —for example, a document incorporated by reference in this prospectus supplement—the statement in the document having the later date modifies or supersedes the earlier statementoffering. We have not authorized anyone to provide any information other than that contained in or incorporated by reference in this prospectus and any related free writing prospectus filed by us with the SEC. We have not, and SVB Leerink has not, authorized anyone to provide you with different or additional information. We take no responsibility forIf anyone provides you with different or inconsistent information, and can provide no assurance as to the reliability of any other information that others may give you. This prospectus supplement does you should not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in this prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawfulrely on it. You should assume that the information appearing in this prospectus supplement, the accompanying base prospectus, any related free writing prospectus, and the documents incorporated by reference in this prospectus supplement and any related free writing the accompanying base prospectus is accurate only as of their the respective datesdates of those documents. Our business, financial condition, results of operations and prospects may have changed materially since those dates. You should also carefully read and consider this prospectus supplement, the accompanying base prospectus, the information in and documents incorporated herein and therein by reference, any related free writing prospectus, and the documents to which we have referred you in additional information under the sections entitled “heading "Where You Can Find More Information” " before making an investment decision . We are not, and “Incorporation the Agent is not, making an offer to sell or soliciting an offer to buy our securities in any jurisdiction in which an offer or solicitation is not authorized or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. We further note that the representations, warranties and covenants made by Reference” us in any agreement that is filed as an exhibit to any document that is incorporated by reference into this prospectus supplementsupplement or the accompanying base prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. Unless otherwise indicated mentioned or unless the context otherwise requiresrequires otherwise, all references in this prospectus supplement to “InflaRx N.V."Netlist,” “InflaRx,” " "the “Company,” “" "we,” “" "us" and "our,” “ours,” “us” or similar terms " refer to InflaRx N.V. Netlist, Inc., a Delaware corporation, and its subsidiariessubsidiaries on a consolidated basis. Basis of Presentation We report our results of operations on a 52- or 53-week fiscal year ending on the Saturday closest to December 31, with each fiscal quarter generally divided into three periods consisting of two four-week periods and one five-week period. Our last three completed fiscal years ended on December 27, 2014, January 2, 2016 and December 31, 2016. Trademarks and Trade Names This prospectus supplement includes our trademarks and service marks, EXPRESSvault®, NVvault®, HyperCloud® and HybriDIMM™, which are protected under applicable intellectual property laws and are the property of the Company. This prospectus supplement may also contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, trademarks and trade names referred to in this prospectus supplement may appear without the ® or ™ symbols. We do not intend our use or display of other parties' trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement and the accompanying prospectus are part of a “shelf” registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or the SEC, on November 24, 2020, and which was declared effective by the SEC on December 22, 2020. This document consists of is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offeringoffering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus and the accompanying prospectus. The second part is the accompanying prospectus, which is part of a registration statement that we filed with the SEC using a “shelf” registration process. The accompanying prospectus describes gives more general informationinformation about the shares of our common stock and other securities we may offer from time to time under our shelf registration statement, some of which may does not apply to this offering. Under this shelf registration process, we may from time to time sell our common shares having an aggregate offering price of up to $50,000,000 under the securities offered by this prospectus supplement at prices and on terms to be determined by market conditions at the time of the offering. Before buying any of the common shares that we are offering, we urge you to carefully read both this prospectus supplement and the accompanying prospectus together with all of the information incorporated by reference herein, as well as the additional information described under the headings “Where You Can Find More Information” and “Incorporation by Reference.” These documents contain important information that you should consider when making your investment decisionsupplement. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in any document incorporated by reference in this prospectus supplementtherein, on the other hand, you should rely on the information in this prospectus supplement. You should read this prospectus supplement, provided that if any statement in one of these the accompanying prospectus, the documents is inconsistent with a statement in another document having a later date —for example, a document incorporated by reference in this prospectus supplement—supplement and the statement in the document having the later date modifies or supersedes the earlier statement. We have not authorized anyone to provide any information other than that contained in or incorporated by reference in this accompanying prospectus and any related free writing prospectus filed by us with the SEC. We have not, and SVB Leerink has not, authorized anyone to provide you with different information. We take no responsibility for, and can provide no assurance as to the reliability of any other information that others may give you. This prospectus supplement does not constitute before making an offer to sell or the solicitation of an offer to buy any securities other than the securities described in this prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus supplement, the documents incorporated by reference and any related free writing prospectus is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed materially since those datesinvestment decision. You should also read and consider the information in the documents referred to which we have referred you in the sections of this prospectus supplement entitled “Where You Can Find More Information” and “Incorporation of Certain Documents by Reference.” in this prospectus supplement. Unless otherwise indicated or the context otherwise requires, all references in In this prospectus supplement to and the accompanying prospectus, unless otherwise indicated, the terms “InflaRx N.V.,” “InflaRx,” the “CompanySonoma,” “we,” “us,” “our,” “ours,” “us” or and similar terms refer to InflaRx N.V. Sonoma Pharmaceuticals, Inc. and its subsidiaries.subsidiaries on a consolidated basis. S-1

ABOUT THIS PROSPECTUS SUPPLEMENT. This document consists of is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offeringoffering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. The second part is part, the accompanying prospectus, which is part of a registration statement that we filed with the SEC using a “shelf” registration process. The accompanying prospectus describes gives more general information, some of which may not apply to this offering. Under Generally, when we refer to this shelf registration processprospectus, we may from time are referring to time sell our common shares having an aggregate offering price both parts of up to $50,000,000 under this document combined. In this prospectus supplement at prices and on terms supplement, as permitted by law, we “incorporate by reference” information from other documents that we file with the SEC. This means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be determined by market conditions at the time a part of the offering. Before buying any of the common shares that we are offering, we urge you to carefully read both this prospectus supplement and the accompanying prospectus together and should be read with all the same care. When we update the information contained in documents that have been incorporated by reference by making future filings with the SEC, the information included or incorporated by reference in this prospectus supplement is considered to be automatically updated and superseded. In other words, in case of a conflict or inconsistency between information contained in this prospectus supplement and information in the accompanying prospectus or incorporated by reference into this prospectus supplement, you should rely on the information contained in the document that was filed later. You should rely only on the information contained in this prospectus supplement and the accompanying prospectus, including the information incorporated by reference herein, herein as well as the additional information described under the headings “Where You Can Find More Information; Incorporation of Documents by Reference,” and “Incorporation by Reference.” These documents contain important information any free writing prospectus that you should consider when making your investment decision. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, we prepare and the information contained in the accompanying prospectus or in any document incorporated by reference in this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement, provided that if any statement in one of these documents is inconsistent with a statement in another document having a later date —for example, a document incorporated by reference in this prospectus supplement—the statement in the document having the later date modifies or supersedes the earlier statementdistribute. We have not authorized anyone to provide any you with information other than that contained in or incorporated by reference in into this prospectus and supplement, the accompanying prospectus or any related free writing prospectus filed related hereto that we may authorize to be delivered to you. If given or made, any such other information or representation should not be relied upon as having been authorized by us us. We may only offer to sell, and seek offers to buy any securities in jurisdictions where offers and sales are permitted. This prospectus supplement and the accompanying prospectus supplement or other offering materials do not contain all of the information included in the registration statement as permitted by the rules and regulations of the SEC. For further information, we refer you to the registration statement on Form S-3, including its exhibits. We are subject to the informational requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and, therefore, file reports and other information with the SEC. We have not, and SVB Leerink has not, authorized anyone to provide you with different information. We take no responsibility for, and can provide no assurance as to the reliability of any other information that others may give you. This prospectus supplement does not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described Statements contained in this prospectus supplement and the accompanying prospectus or other offering materials about the provisions or contents of any agreement or other document are only summaries. If SEC rules require that any agreement or document be filed as an offer exhibit to sell the registration statement, you should refer to that agreement or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawfuldocument for its complete contents. You should assume that the information appearing in this prospectus supplement, the documents accompanying prospectus or any other offering materials is only accurate as of the date on its respective cover, and that any information incorporated by reference and any related free writing prospectus is accurate only as of their respective datesthe date of the document incorporated by reference, unless otherwise indicated. Our business, financial condition, results of operations and prospects may have changed materially since those dates. You should also read and consider the information in the documents to which we have referred you in the sections entitled “Where You Can Find More Information” and “Incorporation by Reference” in this prospectus supplement. Unless otherwise indicated or the context otherwise requires, all references in this prospectus supplement to “InflaRx N.V.,” “InflaRx,” the “Company,” “we,” “our,” “ours,” “us” or similar terms refer to InflaRx N.V. and its subsidiariessuch date.

ABOUT THIS PROSPECTUS SUPPLEMENT. This document consists of two parts. The first part is this prospectus supplement, which describes the specific terms of this offering. The second part is supplement and the accompanying prospectus, which is prospectus are part of a registration statement that we filed with the SEC using a “shelf” registration processstatement on Form S‑3 that we initially filed with the SEC on May 28, 2021 (File No. The accompanying prospectus describes more general information333-256643), some of which may not apply to this offeringand that was declared effective by the SEC on August 3, 2021. Under this the shelf registration process, we may from time to time sell offer shares of our common shares stock having an aggregate offering price of up to $50,000,000 under this prospectus supplement 250,000,000 from time to time at prices and on terms to be determined by market conditions at the time of the offering. Before buying any We provide information to you about this offering of the shares of our common shares stock in two separate documents that we are offering, we urge you to carefully read both this prospectus supplement and the accompanying prospectus together with all of the information incorporated by reference herein, as well as the additional information described under the headings “Where You Can Find More Information” and “Incorporation by Reference.” These documents contain important information that you should consider when making your investment decision. To the extent there is a conflict between the information contained in bound together: (1) this prospectus supplement, on which describes the one hand, specific details regarding this offering; and the information contained in (2) the accompanying prospectus or in any document incorporated by reference base prospectus, which provides general information, some of which may not apply to this offering. Generally, when we refer to this “prospectus,” we are referring to both documents combined. If information in this prospectus supplement, on supplement is inconsistent with the other handaccompanying base prospectus, you should rely on the information in this prospectus supplement. However, provided that if any statement in one of these documents is inconsistent with a statement in another a document having a later date —for example, a document incorporated by reference in this prospectus supplement—, the statement in the document having the later date incorporated by reference modifies or supersedes the earlier statementstatement as our business, financial condition, results of operations and prospects may have changed since the earlier dates. We have not authorized anyone to provide any This prospectus supplement supersedes and replaces the prospectus dated May 28, 2021 in its entirety. You should keep this prospectus supplement for future reference. You should rely only on the information other than that contained in in, or incorporated by reference in into, this prospectus supplement and the accompanying prospectus, and in any related free writing prospectus filed by us that we may authorize for use in connection with the SECthis offering. We have not, and SVB Leerink Xxxxxxx Xxxxx has not, authorized anyone any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We take no responsibility forare not, and can provide no assurance as to the reliability of any other information that others may give you. This prospectus supplement does not constitute Xxxxxxx Xxxxx is not, making an offer to sell or the solicitation of soliciting an offer to buy any securities other than the securities described in this prospectus supplement or an offer to sell or the solicitation of an offer to buy such our securities in any circumstances jurisdiction in which such an offer or solicitation is unlawfulnot authorized or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. You should assume that the information appearing in this prospectus supplementsupplement and the accompanying prospectus, the documents incorporated by reference into this prospectus supplement and the accompanying prospectus, and in any related free writing prospectus that we may authorize for use in connection with this offering, is accurate only as of their the date of those respective datesdocuments. Our business, financial condition, results of operations and prospects may have changed materially since those dates. You should read this prospectus supplement and the accompanying prospectus, the documents incorporated by reference into this prospectus supplement and the accompanying prospectus, and any free writing prospectus that we may authorize for use in connection with this offering, in their entirety before making an investment decision. You should also read and consider the information in the documents to which we have referred you in the sections of this prospectus entitled “Where You Can Find More Information” and “Incorporation of Certain Information by Reference.” We are offering to sell, and seeking offers to buy, shares of common stock only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement and the accompanying prospectus and the offering of the common stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement or the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering of the common stock and the distribution of this prospectus supplement or the accompanying prospectus outside the United States. This prospectus supplement and the accompanying prospectus does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. This prospectus supplement and the accompanying prospectus contain summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated herein by reference as exhibits to the registration statement, and you may obtain copies of those documents as described below under the section titled “Where You Can Find More Information.” We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. This prospectus supplement and the accompanying prospectus contain and incorporate by reference market data and industry statistics and forecasts that are based on independent industry publications and other publicly-available information. Although we believe these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have not independently verified this information. Although we are not aware of any misstatements regarding the market and industry data presented in this prospectus supplement, the accompanying prospectus or the documents incorporated herein by reference, these estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed under the section titled “Risk Factors” in this prospectus supplementsupplement and the accompanying prospectus, and under similar headings in the other documents that are incorporated herein by reference. Accordingly, investors should not place undue reliance on this information. ADMA’s name and logo are either registered trademarks or trademarks of ADMA Biologics, Inc. in the United States and/or other countries. All other trademarks, service marks or other tradenames appearing in this prospectus supplement and the accompanying prospectus are the property of their respective owners. Unless otherwise indicated mentioned or unless the context otherwise requiresrequires otherwise, all references in this prospectus supplement and the accompanying prospectus to the “InflaRx N.V.Company,” “InflaRx,” the “CompanyADMA,” “we,” “ourus,” “ours,” “usour” or similar terms refer to InflaRx N.V. references mean ADMA Biologics, Inc., a Delaware corporation, and its wholly owned subsidiaries, ADMA BioCenters Georgia, Inc., a Delaware corporation (“ADMA BioCenters”), ADMA BioManufacturing, LLC, a Delaware limited liability company (“ADMA BioManufacturing”), and ADMA Plasma Biologics, Inc., a Delaware corporation (“ADMA Plasma Biologics”). This prospectus supplement and the accompanying prospectus include our trademarks, trade names and service marks, such as “ASCENIVTM, ” “Nabi-HB®” and “BIVIGAM®,” which are protected under applicable intellectual property laws and are the property of ADMA Biologics, Inc., or its subsidiaries. Solely for convenience, trademarks, trade names and service marks referred to in this prospectus supplement may appear without the ®, TM or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other parties’ trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement and the accompanying prospectus are part of a shelf registration statement that we filed with the Securities and Exchange Commission, or the SEC. This prospectus supplement amends and supplements the information in the prospectus filed as a part of our registration statement on Form S-3 (File No. 333-221724), which was declared effective as of December 1, 2017, or the Registration Statement. This prospectus supplement should be read in conjunction with the accompanying prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the accompanying prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the accompanying prospectus, and any future amendments or supplements thereto. Our Registration Statement allows us to offer from time to time a wide array of securities. In the accompanying prospectus, we provide you with a general description of the securities we may offer from time to time under our Registration Statement and other general information that may apply to this offering. Both this prospectus supplement and the accompanying prospectus include important information about us, our common stock and other information that you should know before investing. You should carefully read both this prospectus supplement and the accompanying prospectus as well as additional information described under “Where You Can Find More Information” before investing in our securities. This document consists of is in two parts. The first part is this prospectus supplement, which describes adds to and updates information contained in the specific terms of this offeringaccompanying prospectus. The second part is part, the accompanying prospectus, which is part of a registration statement that we filed with the SEC using a “shelf” registration process. The accompanying prospectus describes provides more general information, some of which may not apply to this offering. Under Generally, when we refer to this shelf registration process, we may from time to time sell our common shares having an aggregate offering price of up to $50,000,000 under this “prospectus supplement at prices and on terms to be determined by market conditions at the time of the offering. Before buying any of the common shares that supplement,” we are offering, we urge you referring to carefully read both this prospectus supplement and the accompanying prospectus together with all of the information incorporated by reference hereinprospectus, as well as the additional documents incorporated by reference herein and therein. If information described under the headings “Where You Can Find More Information” and “Incorporation by Reference.” These documents contain important information that you should consider when making your investment decision. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in supplement is inconsistent with the accompanying prospectus or in any document incorporated by reference in this prospectus supplement, on the other handprospectus, you should rely on the information in this prospectus supplement. We further note that the representations, provided warranties and covenants made by us in any agreement that if is filed as an exhibit to any statement in one of these documents document that is inconsistent with a statement in another document having a later date —for example, a document incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in this prospectus supplement—some cases, for the statement in purpose of allocating risk among the document having the later date modifies or supersedes the earlier statement. We have not authorized anyone parties to provide any information other than that contained in or incorporated by reference in this prospectus and any related free writing prospectus filed by us with the SEC. We have notsuch agreements, and SVB Leerink has notshould not be deemed to be a representation, authorized anyone warranty or covenant to provide you with different information. We take no responsibility for, and can provide no assurance as to the reliability of any other information that others may give you. This prospectus supplement does not constitute an offer to sell Moreover, such representations, warranties or the solicitation of an offer to buy any securities other than the securities described in this prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus supplement, the documents incorporated by reference and any related free writing prospectus is covenants were accurate only as of their respective datesthe date when made. Our businessAccordingly, financial conditionsuch representations, results warranties and covenants should not be relied on as accurately representing the current state of operations and prospects may have changed materially since those datesour affairs. You should also read and consider the information in the documents to which we have referred you in the sections entitled “Where You Can Find More Information” and “Incorporation by Reference” As used in this prospectus supplement. Unless otherwise indicated or the context otherwise requiresprospectus, all references in this prospectus supplement to “InflaRx N.V.,” “InflaRxCohBar,” the “Company,” “we,” “our,” “ours,” or “us” refers to CohBar, Inc. COHBARTM and other trademarks or similar terms refer to InflaRx N.V. service marks of CohBar, Inc. appearing in this prospectus are the property of CohBar, Inc. Trade names, trademarks and its subsidiariesservice marks of other companies appearing in this prospectus are the property of their respective holders.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement and the accompanying prospectus are part of a registration statement that we filed with the Securities and Exchange Commission, or SEC, utilizing a “shelf” registration process. This document consists of is in two parts. The first part is this the prospectus supplement, including the documents incorporated herein by reference, which describes the specific terms of this offering. The second part is the accompanying prospectus, including the documents incorporated therein by reference, which is part of a registration statement that we filed with the SEC using a “shelf” registration process. The accompanying prospectus describes provides more general informationinformation about securities we may offer from time to time, some of which may not apply to this offering. Under this shelf registration process, we may from time to time sell our common shares having an aggregate offering price of up to $50,000,000 under this prospectus supplement at prices and on terms to be determined by market conditions at the time of the offering. Before buying any of the common shares that we are offering, we We urge you to carefully read both this prospectus supplement and the accompanying prospectus together with all of prospectus, and the information documents incorporated by reference hereinherein and therein, as well as before buying any of the additional securities being offered under this prospectus supplement. This prospectus supplement may add or update information described under contained in the headings “Where You Can Find More Information” prospectus and “Incorporation the documents incorporated by Reference.” These documents contain important information that you should consider when making your investment decisionreference therein. To the extent there is a conflict between the information contained that any statement we make in this prospectus supplement, on the one hand, and the information contained supplement is inconsistent with statements made in the accompanying prospectus or in any document documents incorporated by reference in therein that were filed before the date of this prospectus supplement, on the other hand, you should rely on the information statements made in this prospectus supplement, provided that if supplement will be deemed to modify or supersede those made in the accompanying prospectus and such documents incorporated by reference therein. If any statement in one of these documents is inconsistent with a statement in another document having a later date —– for example, a document incorporated by reference in this the accompanying prospectus supplement—– the statement in the document having the later date modifies or supersedes the earlier statement. We have not authorized anyone to provide any You should rely only on the information other than that contained in or incorporated by reference in this prospectus supplement and the accompanying prospectus, or contained in any related free writing prospectus filed prepared by us with the SECor on our behalf. We have not, and SVB Leerink the placement agent has not, authorized anyone to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. The distribution of this prospectus supplement and sale of these securities in certain jurisdictions may be restricted by law. We take no responsibility for, are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. Persons in possession of this prospectus supplement or the accompanying prospectus are required to inform themselves about and can provide no assurance as to the reliability of observe any other information that others may give yousuch restrictions. This prospectus supplement does not constitute and the accompanying prospectus are not, and under no circumstances are to be construed as, an advertisement or a public offering of securities in Israel. Any public offer to sell or sale of securities in Israel may be made only in accordance with the Israeli Securities Law, 5728-1968, or the solicitation Securities Law (which requires, among other things, the filing of an offer to buy any securities other than the securities described a prospectus in this prospectus supplement Israel or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawfulexemption therefrom). You should assume that the The information appearing contained in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference in this prospectus supplement and the accompanying prospectus, and in any related free writing prospectus that we have authorized for use in connection with this offering, is accurate only as of their the date of those respective datesdocuments regardless of the time of delivery of this prospectus supplement or the accompanying prospectus or when any sale of our securities occurs. Our business, financial condition, results of operations and prospects may have changed materially since those dates. You should read this prospectus supplement, the accompanying prospectus and the documents incorporated by reference in this prospectus supplement and the accompanying prospectus, in their entirety, before making an investment decision. You should also read and consider the information in the documents to which we have referred you in the sections of this prospectus supplement entitled “Where You Can Find More Information” and “Incorporation of Certain Documents by Reference.” This prospectus supplement and the accompanying prospectus contain summaries of certain provisions contained in this prospectus supplementsome of the documents described herein, but reference is made to the actual documents for complete information. Unless otherwise indicated All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated herein by reference as exhibits to the context otherwise requiresregistration statement, all references and you may obtain copies of those documents as described below under the section entitled “Where You Can Find More Information.” We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. Certain figures included in this prospectus supplement have been subject to rounding adjustments. Accordingly, figures shown as totals in certain tables may not be an arithmetic aggregation of the figures that precede them. As used herein, and unless the context suggests otherwise, the terms “InflaRx N.V.,” “InflaRx,” the “CompanyEvogene,” “we,” “us,” “our,” “ours,our company” and “usthe company” refer to Evogene Ltd. and its consolidated subsidiaries, consisting of AgPlenus Ltd., Biomica Ltd., Canonic Ltd., Casterra Ag Ltd., Evogene Inc., Lavie Bio Ltd. and their consolidated subsidiaries. References to “dollar” and “$” are to U.S. dollars, the lawful currency of the United States, and references to “NIS” are to New Israeli Shekels, the lawful currency of the State of Israel. References to our “ordinary shares” or similar terms “shares” refer to InflaRx N.V. and its subsidiariesour ordinary shares, par value NIS 0.02 per share. References to our “2019 annual report” refer to our Annual Report on Form 20-F for the year ended December 31, 2019, which we filed with the SEC on April 27, 2020.

ABOUT THIS PROSPECTUS SUPPLEMENT. This document consists of two parts. The first part is this prospectus supplement, which describes the specific terms of this offering. The second part is the accompanying prospectus, which is part of a registration statement that we filed with the SEC using a “shelf” registration process. The accompanying prospectus describes more general information, some of which may not apply to this offering. Under this shelf registration process, we may from time to time sell our common shares having an aggregate offering price of up to $50,000,000 under this prospectus supplement at prices and on terms to be determined by market conditions at the time of the offering. Before buying any of the common shares that we are offering, we urge you to carefully read both this prospectus supplement and the accompanying prospectus together with all of the information incorporated by reference herein, as well as the additional information described under the headings “Where You Can Find More Information” and “Incorporation by Reference.” These documents contain important information that you should consider when making your investment decision. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in any document incorporated by reference in this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement, provided that if any statement in one of these documents is inconsistent with a statement in another document having a later date —for example, a document incorporated by reference in this prospectus supplement—the statement in the document having the later date modifies or supersedes the earlier statement. We have not authorized anyone to provide any information other than that contained in or incorporated by reference in this prospectus and any related free writing prospectus filed by us with the SEC. We have not, and SVB Leerink has not, authorized anyone to provide you with different information. We take no responsibility for, and can provide no assurance as to the reliability of any other information that others may give you. This prospectus supplement does not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in this prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus supplement, the documents incorporated by reference and any related free writing prospectus is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed materially since those dates. You should also read and consider the information in the documents to which we have referred you in the sections entitled “Where You Can Find More Information” and “Incorporation by Reference” in this prospectus supplement. Unless otherwise indicated or the context otherwise requires, all references in this prospectus supplement to “InflaRx N.V.,” “InflaRx,” the “Company,” “we,” “our,” “ours,” “us” or similar terms refer to InflaRx N.V. and its subsidiaries.

ABOUT THIS PROSPECTUS SUPPLEMENT. This document consists of two parts. The first part is this prospectus supplement, which describes the specific terms of this offering. The second part is the accompanying prospectus, which is part of a registration statement that we filed with the SEC using a “shelf” registration process. The accompanying prospectus describes more general information, some of which may not apply to this offering. Under this shelf registration process, we may from time to time sell our common shares having an aggregate offering price of up to $50,000,000 5,000,000 of our ordinary shares, par value NIS 0.0000769 per share under this prospectus supplement at prices and on terms to be determined by market conditions at the time of the offering. The maximum offering price under this prospectus supplement shall not exceed the amount available under our prospectus filed on Form F-3 on July 13, 2020. Before buying any of the common ordinary shares that we are offering, we urge you to carefully read both this prospectus supplement and the accompanying prospectus together with all of the information incorporated by reference herein, as well as the additional information described under the headings “Where You Can Find More Information” and “Incorporation by Reference.” These documents contain important information that you should consider when making your investment decision. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in any document incorporated by reference in this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement, provided that if any statement in one of these documents is inconsistent with a statement in another document having a later date date—for example, a document incorporated by reference in this prospectus supplement—the statement in the document having the later date modifies or supersedes the earlier statement. We have not authorized anyone to provide any information other than that contained in or incorporated by reference in this prospectus supplement, the accompanying prospectus and any related free writing prospectus filed by us with the SEC. We have not, and SVB Leerink X. Xxxxx Securities has not, authorized anyone to provide you with different information. We take no responsibility for, and can provide no assurance as to the reliability of any other information that others may give you. This prospectus supplement does not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in this prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus supplement, the documents incorporated by reference and any related free writing prospectus is are accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed materially since those dates. You should also read and consider the information in the documents to which we have referred you in the sections entitled “Where You Can Find More Information” and “Incorporation by Reference” in this prospectus supplement. Unless otherwise indicated or the context otherwise requiresindicated, all references in this prospectus supplement to “InflaRx N.V.,” “InflaRx,” the “Company,” “we,” “ourus,” “oursour” and “Entera” refer to Entera Bio Ltd. and its wholly owned subsidiary, Entera Bio Inc., a Delaware corporation, unless the context otherwise requires. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS Various statements in this report are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. In addition, historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials would not be different, and historic results referred to in this Annual Report may be interpreted differently in light of additional research and clinical and preclinical trials results. Forward-looking statements include all statements that are not historical facts. We have based these forward-looking statements largely on our management’s current expectations and future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Forward-looking statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this report regarding our strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management are forward- looking statements. These statements are subject to risks and uncertainties and are based on information currently available to our management. Words such as, but not limited to, “anticipate,” “usbelieve,” “contemplates,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “likely,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “will,” “would,” “seek,” “should,” “target,” or the negative of these terms and similar terms refer expressions or words, identify as forward-looking statements. The events and circumstances reflected in our forward-looking statements may not occur and actual results could differ materially from those projected in our forward-looking statements. Meaningful factors which could cause actual results to InflaRx N.V. differ include, but are not limited to: • the scope, progress and costs of developing our product candidates such as EB613 for Osteoporosis and EB612 for Hypoparathyroidism, including without limitation any changes to the design of the ongoing Phase 2 clinical trial of EB613 or the need for additional clinical trials or development work based on further analysis of the interim data from the ongoing EB613 Phase 2 clinical trial; • the accuracy of our estimates regarding expenses, capital requirements, the sufficiency of our cash resources and the need for additional financing; • our ability to raise additional funds on commercially reasonable terms; • our ability to develop, advance product candidates into, and successfully complete, clinical studies such as our ongoing Phase 2 clinical trial of EB613 in osteoporosis; • our reliance on third parties to conduct our clinical trials and on third-party suppliers to supply or produce our product candidates; • our interpretation of FDA feedback and guidance and how such guidance may impact our clinical development plans, specifically our ability to utilize the 505(b)(2) pathway for the development and potential approval of EB613 and any other product candidates we may develop; • our expectations regarding licensing, business transactions and strategic collaborations, including our ongoing collaboration with Amgen; • our ability to use and expand our drug delivery technology to additional product candidates; • our operation as a development stage company with limited operating history and a history of operating losses and our ability to fund our operations going forward; • our ability to continue as a going concern absent access to sources of liquidity; • our ability to obtain and maintain regulatory approval for any of our product candidates; • our competitive position, especially with respect to Forteo® and other products on the market or in development for the treatment of osteoporosis; • our ability to establish and maintain development and commercialization collaborations; • any potential commercial launch of current or future product candidates, and the timing, cost or other aspects of such commercialization; • our ability to manufacture and supply sufficient amounts of material to support our clinical trials and any potential future commercial requirements; • the safety and efficacy of therapeutics marketed by competitors that are targeted toward indications for which we are developing product candidates; • the size of any market we may target and the adoption of our product candidates, if approved, by physicians and patients; • our ability to obtain, maintain and protect our intellectual property and operate our business without infringing misappropriating or otherwise violating any intellectual property rights of others; • our ability to retain key personnel and recruit additional qualified personnel; • the possibility that competing products or technologies may make any product candidates we may develop and commercialize or our oral delivery technology obsolete; • the pricing and reimbursement of our product candidates, if approved; • our ability to develop a sales, marketing and distribution infrastructure, if any; • our ability to manage growth; and • the duration and severity of the recent coronavirus (COVID-19) outbreak, the actions that may be required to contain the coronavirus or treat its impact, and its subsidiariesimpact on our operations and workforce, including our research and development and clinical trials. All written and verbal forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. We caution investors not to rely too heavily on the forward-looking statements we make or that are made on our behalf. Except as required by law, we are under no duty, and expressly disclaim any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in any annual, quarterly or current reports that we may file with the Securities and Exchange Commission. There can be no assurance that the actual results or developments anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on us. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

ABOUT THIS PROSPECTUS SUPPLEMENT. This document is part of the registration statement that we filed with the Securities and Exchange Commission, or the SEC, using a “shelf” registration process and consists of two parts. The first part is this prospectus supplement, including the documents incorporated by reference, which describes the specific terms of this offering. The second part is offering and also adds to and updates information contained in the accompanying prospectus, which is part of a registration statement that we filed with the SEC using a “shelf” registration process. The accompanying prospectus describes more general information, some of which may not apply to this offering. Under this shelf registration processprospectus supplement, we may from time to time sell ADSs representing our common ordinary shares having an aggregate offering price of up to $50,000,000 75 million in sales deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act. The second part, the accompanying prospectus, including the documents incorporated by reference, gives more general information, some of which may not be applicable to this offering. Generally, when we refer to the “prospectus” we are referring to both parts combined. If information in this prospectus supplement at prices and on terms to be determined by market conditions at the time of the offering. Before buying any of the common shares that we are offering, we urge you to carefully read both this prospectus supplement and the accompanying prospectus together is inconsistent with all of the information incorporated by reference herein, as well as the additional information described under the headings “Where You Can Find More Information” and “Incorporation by Reference.” These documents contain important information that you should consider when making your investment decision. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in with any document incorporated by reference in that was filed with the SEC before the date of this prospectus supplement, on the other hand, you should rely on the information this prospectus supplement. If any statement in this prospectus supplement, provided that if any statement in one of these documents supplement or the accompanying prospectus is inconsistent with a statement in another document that is incorporated by reference into this prospectus and having a later date —for exampledate, a document incorporated by reference in this prospectus supplement—the statement in the document having the later date modifies or supersedes the earlier statement. We have Any statement so modified or superseded will not authorized anyone be deemed, except as so modified or superseded, to provide any information other than that contained in or constitute a part of this prospectus. This prospectus supplement, the accompanying prospectus and the documents incorporated by reference in this prospectus into each include important information about us, the ADSs being offered and any related free writing prospectus filed by us with the SEC. We have not, and SVB Leerink has not, authorized anyone to provide you with different information. We take no responsibility for, and can provide no assurance as to the reliability of any other information that others may give youyou should know before investing in our ADSs. This prospectus supplement does not constitute an offer You should also read and consider information in the documents we have referred you to sell or in the solicitation sections of an offer to buy any securities other than the securities described in this prospectus supplement or an offer to sell or and the solicitation accompanying prospectus entitled “Incorporation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. Information by Reference” and “Where You Can Find More Information.” You should assume that the information appearing in this prospectus supplement, supplement and the documents incorporated by reference and any related free writing accompanying prospectus is accurate only as of their the date on the front of the respective datesdocument and that any information that we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus supplement or the accompanying prospectus or the time of any sale of an ADS. Our business, financial condition, liquidity, results of operations and prospects may have changed materially since those dates. You should also read This prospectus supplement and consider the information accompanying prospectus contain summaries of certain provisions contained in some of the documents described herein, but reference is made to which we the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have referred been filed, will be filed or will be incorporated herein by reference as exhibits to the registration statement, and you in may obtain copies of those documents as described below under the sections entitled “Incorporation of Information by Reference” and “Where You Can Find More Information.” We further note that the representations, warranties and “Incorporation covenants made by Reference” us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. Neither we nor SVB Securities are making offers to sell or solicitations to buy our ADSs in any jurisdiction in which an offer or solicitation is not permitted or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. For investors outside the United States: Neither we nor SVB Securities have done anything that would permit this offering or possession or distribution of this prospectus supplementsupplement in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus supplement must inform themselves about, and observe any restrictions relating to, the offering of the securities described herein and the distribution of this prospectus supplement outside the United States. Unless otherwise indicated or the context otherwise requires, all references in this prospectus supplement to “InflaRx N.V.Innate,” “InflaRx,” the “Company,” “we,” “ourus,” and “ours,our” “us” or similar terms refer to InflaRx N.V. Innate Pharma S.A. and its subsidiariesconsolidated subsidiary.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement and the accompanying prospectus are part of a “shelf” registration statement on Form S-3 (File No. 333-234107) that we initially filed with the SEC on October 4, 2019, and that was declared effective by the SEC on October 15, 2019. This document consists of is in two parts. The first part is this prospectus supplement, which supplement describes the specific terms of this offeringoffering of our common stock and adds to and updates the information contained in the accompanying prospectus. The second part is part, the accompanying prospectus, which is part of a registration statement that we filed with the SEC using a “shelf” registration process. The accompanying prospectus describes provides more general information, some of which may not apply to this offering. Under Generally, when we refer to this shelf registration processprospectus, we may from time are referring to time sell our common shares having an aggregate offering price both parts of up to $50,000,000 under this prospectus supplement at prices and on terms to be determined by market conditions at the time of the offering. Before buying any of the common shares that we are offering, we urge you to carefully read both this prospectus supplement and the accompanying prospectus together with all of the information incorporated by reference herein, as well as the additional information described under the headings “Where You Can Find More Information” and “Incorporation by Reference.” These documents contain important information that you should consider when making your investment decisiondocument combined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, supplement and the information contained in the accompanying prospectus or in any document incorporated by reference in this prospectus supplement, on the other handprospectus, you should rely on the information in this prospectus supplement. This prospectus supplement and the accompanying prospectus relate to the offering of shares of our common stock. Before buying any of the shares of common stock offered hereby, provided that if any statement in one of these documents is inconsistent we urge you to read carefully this prospectus supplement and the accompanying prospectus, together with a statement in another document having a later date —for example, a document the information incorporated herein by reference in this as described below under the heading “Incorporation of Certain Documents by Reference.” This prospectus supplement—supplement contains information about the statement common stock offered hereby and may add to, update or change information in the document having accompanying prospectus. You should rely only on the later date modifies or supersedes the earlier statement. We have not authorized anyone to provide any information other than that contained in in, or incorporated by reference in into, this prospectus supplement and any related free writing prospectus filed by us with the SECaccompanying prospectus. We have not, and SVB Leerink Jefferies has not, authorized anyone to provide you with different or additional information. We take no responsibility for, and can provide no assurance as to the reliability of any other information that others may give you. This prospectus supplement does are not constitute an offer making offers to sell or the solicitation of an offer solicitations to buy any securities other than the securities described in this prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities our common stock in any circumstances jurisdiction in which such an offer or solicitation is unlawfulnot authorized or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. You should assume that the information appearing in this prospectus supplement, supplement and the documents incorporated by reference and any related free writing accompanying prospectus is accurate only as of their the dates on the front of the respective datesdocuments and that any information that we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus supplement or the accompanying prospectus or the time of any sale of a security. Our business, financial condition, results This prospectus supplement and the accompanying prospectus contain summaries of operations and prospects may have changed materially since those dates. You should also read and consider the information certain provisions contained in some of the documents described herein, but reference is made to which we the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have referred been filed, will be filed or will be incorporated herein by reference as exhibits to the registration statement, and you in may obtain copies of those documents as described below under the sections entitled section titled “Where You Can Find More Information.” We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. This prospectus supplement and the accompanying prospectus contain and incorporate by reference market data and industry statistics and forecasts that are based on independent industry publications and other publicly-available information. Although we believe these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have not independently verified this information. Although we are not aware of any misstatements regarding the market and industry data presented in this prospectus supplement, accompanying prospectus or the documents incorporated herein by reference, these estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed under the section titled “Incorporation by ReferenceRisk Factors” in this prospectus supplementsupplement and the accompanying prospectus, and under similar headings in the other documents that are incorporated herein by reference. Accordingly, investors should not place undue reliance on this information. ADMA’s name and logo are either registered trademarks or trademarks of ADMA Biologics, Inc. in the United States and/or other countries. All other trademarks, service marks or other tradenames appearing in this prospectus supplement and the accompanying prospectus are the property of their respective owners. Unless otherwise indicated mentioned or unless the context otherwise requiresrequires otherwise, all references in this prospectus supplement and the accompanying prospectus to the “InflaRx N.V.Company,” “InflaRx,” the “CompanyADMA,” “we,” “ourus,” “oursour” or similar references mean ADMA Biologics, Inc., a Delaware corporation, and its wholly owned subsidiaries, ADMA Plasma Biologics, Inc., a Delaware corporation (“ADMA Plasma Biologics”), ADMA BioCenters Georgia, Inc., a Delaware corporation (“ADMA BioCenters”), and ADMA BioManufacturing, LLC, a Delaware limited liability company (“ADMA BioManufacturing”). This prospectus supplement includes our trademarks, trade names and service marks, such as “ASCENIVTM,” “usNabi-HB®” and “BIVIGAM®,” which are protected under applicable intellectual property laws and are the property of ADMA Biologics, Inc., or similar terms refer to InflaRx N.V. and its subsidiaries. Solely for convenience, trademarks, trade names and service marks referred to in this prospectus supplement may appear without the ®, TM or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other parties’ trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.

ABOUT THIS PROSPECTUS SUPPLEMENT. This document consists of two parts. The first part is this the prospectus supplement, which describes the specific terms of this offeringoffering and the Offered Stock. The second part is the accompanying prospectus, which is part of a registration statement that we filed with the SEC using a “shelf” registration process. The accompanying prospectus describes more general information, some of which may not apply to this offering. Under this shelf registration process, we may from time to time sell our common Before you buy any shares having an aggregate offering price of up to $50,000,000 under this prospectus supplement at prices and on terms to be determined by market conditions at the time of the offering. Before buying any of the common shares that we are offeringOffered Stock, we urge it is important for you to carefully read both and consider the information contained in this prospectus supplement and the accompanying prospectus together with all of the information incorporated by reference herein, as well as the additional information described under the headings “Incorporation by Reference of Information Filed with the SEC” and “Where You Can Find More Information” and “Incorporation by Reference.” These documents contain important information that you should consider when making your investment decisionin this prospectus supplement. To the extent there is the information set forth in this prospectus supplement differs in any way from the information set forth in the accompanying prospectus or the documents incorporated by reference in this prospectus supplement or the accompanying prospectus from a conflict between filing we made with the Securities and Exchange Commission, or the SEC, under the Securities Exchange Act of 1934, as amended, or the Exchange Act, prior to the date of this prospectus supplement, the information in this prospectus supplement will supersede such information. In addition, to the extent any information incorporated by reference in this prospectus supplement or the accompanying prospectus from a filing we make with the SEC after the date of this prospectus supplement adds to, updates or changes information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in any document an earlier filing we made with the SEC that is incorporated by reference in this prospectus supplementsupplement or the accompanying prospectus, on the other handinformation in such later filing shall be deemed to modify, you should rely on the update and, where applicable, supersede such information in this prospectus supplement, provided that if any statement in one of these documents is inconsistent with a statement in another document having a later date —for example, a document incorporated by reference in this the accompanying prospectus supplement—the statement in the document having the later date modifies or supersedes the earlier statement. We have not authorized anyone to provide any information other than that contained in or incorporated by reference in this prospectus and any related free writing prospectus filed by us filing with the SEC. We have not, and SVB Leerink has not, authorized anyone to provide you with different information. We take no responsibility for, and can provide no assurance as to the reliability of any other information that others may give you. This prospectus supplement does not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in this prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in In this prospectus supplement, the documents incorporated by reference and any related free writing prospectus is accurate only we refer to New York Mortgage Trust, Inc., a Maryland corporation, together with its consolidated subsidiaries, as of their respective dates. Our business, financial condition, results of operations and prospects may have changed materially since those dates. You should also read and consider the information in the documents to which we have referred you in the sections entitled “Where You Can Find More Information” and “Incorporation by Reference” in this prospectus supplement. Unless otherwise indicated or the context otherwise requires, all references in this prospectus supplement to “InflaRx N.V.,” “InflaRx,” the “Company,” “we,” “us,” “the Company” or “our,” “ours,” “us” unless we specifically state otherwise or similar terms the context indicates otherwise, and refer to InflaRx N.V. and its subsidiariesour wholly-owned taxable REIT subsidiaries as “TRSs.” In addition, the following defines certain of the commonly used terms in this prospectus supplement:

ABOUT THIS PROSPECTUS SUPPLEMENT. This document consists of is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offeringoffering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference herein. The second part is the accompanying prospectus, which is part of a registration statement that we filed with the SEC using a “shelf” registration process. The accompanying prospectus describes provides more general informationinformation about securities we may offer from time to time, some of which may does not apply to this offering. Under Generally, when we refer to this shelf registration processprospectus, we may from time are referring to time sell our common shares having an aggregate offering price both parts of up to $50,000,000 under this document combined. This prospectus supplement at prices may add, update or change information contained in the accompanying prospectus and on terms to be determined the documents incorporated by market conditions at the time of the offering. Before buying any of the common shares that we are offering, we urge you to carefully read both reference into this prospectus supplement and the accompanying prospectus together with all of the information incorporated by reference herein, as well as the additional information described under the headings “Where You Can Find More Information” and “Incorporation by Reference.” These documents contain important information that you should consider when making your investment decisionprospectus. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, supplement and the information contained in the accompanying prospectus or in any document incorporated by reference in therein filed prior to the date of this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement, ; provided that if any statement in one of these documents is inconsistent with a statement in another document having a later date —— for example, a document incorporated by reference in this the accompanying prospectus supplement—— the statement in the document having the later date modifies or supersedes the earlier statement. We have not Neither we nor Canaccord has authorized anyone to provide any information other than that contained in or incorporated by reference in into this prospectus and supplement, the accompanying prospectus or in any related free writing prospectus filed prepared by or on behalf of us with the SECor to which we have referred you. We have not, and SVB Leerink has not, authorized anyone to provide you with different information. We Canaccord take no responsibility for, and can provide no assurance as to the reliability of of, any other information that others may give you. This prospectus supplement does and the accompanying prospectus do not constitute an offer to sell sell, or the a solicitation of an offer to buy any securities other than purchase, the securities described offered by this prospectus supplement and the accompanying prospectus in any jurisdiction to or from any person to whom or from whom it is unlawful to make such offer or solicitation of an offer in such jurisdiction. The information contained in this prospectus supplement or an offer the accompanying prospectus, or incorporated by reference herein or therein, is accurate only as of the respective dates thereof, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or of any sale of our Class A common stock. It is important for you to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the read and consider all information appearing contained in this prospectus supplementsupplement and the accompanying prospectus, including the documents incorporated by reference herein and any related free writing prospectus is accurate only as of their respective dates. Our businesstherein, financial condition, results of operations and prospects may have changed materially since those datesin making your investment decision. You should also read and consider the information in the documents to which we have referred you in the sections entitled “Where You Can Find More Information” and “Incorporation of Certain Documents by Reference” in this prospectus supplementsupplement and in the accompanying prospectus. We are offering to sell, and seeking offers to buy, shares of our Class A common stock only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement and the accompanying prospectus and the offering of the Class A common stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement and the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering of the Class A common stock and the distribution of this prospectus supplement and the accompanying prospectus outside the United States. This prospectus supplement and the accompanying prospectus do not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. Unless otherwise indicated or the context otherwise requiresindicates, all references in this prospectus supplement to “InflaRx N.V.Blue Apron,” “InflaRx,” the “Company,” company “ “we,” “our,” “ours,” and “us” or similar terms refer refer, collectively, to InflaRx N.V. Blue Apron Holdings, Inc., a Delaware corporation, and its consolidated subsidiaries.

ABOUT THIS PROSPECTUS SUPPLEMENT. This document consists prospectus supplement and the accompanying prospectus relate to an offering of two partsour Common Stock. The first part is Before investing in our Common Stock offered by this prospectus supplement, which describes the specific terms of this offering. The second part is the accompanying prospectus, which is part of a registration statement that we filed with the SEC using a “shelf” registration process. The accompanying prospectus describes more general information, some of which may not apply to this offering. Under this shelf registration process, we may from time to time sell our common shares having an aggregate offering price of up to $50,000,000 under this prospectus supplement at prices and on terms to be determined by market conditions at the time of the offering. Before buying any of the common shares that we are offering, we urge you to carefully read both this prospectus supplement and the accompanying prospectus prospectus, together with all of the information incorporated by reference herein, as well as the additional information described under the headings “Where You Can Find More Information” and “Incorporation by Reference.” in this prospectus supplement. These documents contain important information that you should consider when making your investment decision. This document is in two parts. The first part is this prospectus supplement, which describes the terms of this offering and also adds to, updates and changes information contained in the accompanying prospectus and the documents incorporated by reference. The second part is the accompanying prospectus, which gives more general information. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and supplement differs from or conflicts with the information contained in the accompanying prospectus or in any document incorporated by reference in this prospectus supplementreference, on the other hand, you should rely on the information in this prospectus supplement, provided that if supplement will control. If any statement in one of these documents is inconsistent with a statement in another document having a later date date—for example, a document incorporated by reference in into this prospectus supplementsupplement or the accompanying prospectus—the statement in the document having the later date modifies or supersedes the earlier statement. We have In deciding whether or not authorized anyone to provide any invest in our Common Stock, you should rely only on the information other than that contained in in, or incorporated by reference in into, this prospectus supplement, the accompanying prospectus and any related free writing prospectus filed by us that we have authorized for use in connection with this offering. Neither we nor the SEC. We Agents have not, and SVB Leerink has not, authorized anyone to provide you with different informationinformation or to make any representation other than those contained in, or incorporated by reference into, this prospectus supplement, the accompanying prospectus and any related free writing prospectus. We take no responsibility forIf anyone provides you with different or inconsistent information or representation, and can provide no assurance as to the reliability of any other information that others may give youyou should not rely on them. This prospectus supplement does and the accompanying prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in this prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities our Common Stock in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus supplement, the documents incorporated by reference accompanying prospectus and any related free writing prospectus and the documents incorporated by reference is accurate only as of their respective dates, regardless of the time of delivery of this prospectus supplement, the accompanying prospectus or any related free writing prospectus or any sale of our Common Stock. Our business, financial condition, results of operations and prospects may have changed materially since those dates. You should also read We further note that the representations, warranties and consider the information covenants made by us in the documents any agreement that is filed as an exhibit to which we have referred you in the sections entitled “Where You Can Find More Information” and “Incorporation any document that is incorporated by Reference” in reference into this prospectus supplementsupplement or the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our business, financial condition, results of operations or prospects. Unless otherwise indicated or the context otherwise requiresrequires otherwise, all references in this prospectus supplement to “InflaRx N.V.,” “InflaRxTeraWulf,” the “Company,” the “Registrant,” “we,” “our,” “ours,” “us” or similar terms and “our” refer to InflaRx N.V. and TeraWulf Inc. together with its consolidated subsidiaries.

ABOUT THIS PROSPECTUS SUPPLEMENT. This document consists of two parts. The first part is this prospectus supplement, which describes the specific terms of this offering. The second part is supplement and the accompanying prospectus, which is prospectus are part of a registration statement on Form S-3 that we filed with the SEC using Securities and Exchange Commission, which we refer to as the “SEC,” utilizing a “shelf” registration process. The accompanying prospectus describes more general information, some of which may not apply to this offering. Under this shelf registration process, we may from time to time sell offer shares of our common shares stock having an aggregate offering price of up to $50,000,000 125,000,000 under this prospectus supplement at prices and on terms to be determined by market conditions at the time of each such offering. We are providing information to you about this offering of our common stock in two parts. The first part is this prospectus supplement, which provides you with specific information regarding the offeringterms of this offering and our common stock, and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference in this prospectus supplement and the accompanying prospectus. The second part is the accompanying prospectus, which provides more general information, some of which does not apply to this offering of our common stock. Before buying any of the common shares stock that we are offering, we urge you to carefully read both this prospectus supplement and the accompanying prospectus together with all of the information incorporated by reference herein, as well as the additional information described under the headings “Where You Can Find More Information” and “Incorporation of Certain Information by Reference.” These documents contain important information that you should consider when making your investment decision. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in any document incorporated by reference in this prospectus supplement that was filed with the SEC before the date of this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement, provided that if . If any statement in one of these documents is inconsistent with a statement in another document having a later date date—for example, a document incorporated by reference in this prospectus supplement—the statement in the document having the later date modifies or supersedes the earlier statement. We have not authorized anyone further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to provide any information other than document that contained in or is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in this prospectus some cases, for the purpose of allocating risk among the parties to such agreement, and any related free writing prospectus filed by us with should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the SECdate when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. We have not, and SVB Leerink Cowen has not, authorized anyone to provide you with different informationany information other than that contained or incorporated by reference in this prospectus supplement and in the accompanying prospectus or in any related free writing prospectus that we authorize for use in connection with this offering and to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of of, any other information that others may give you. If anyone provides you with different or inconsistent information, you should not rely on it. You should assume that the information appearing in this prospectus supplement, the documents incorporated by reference and the accompanying prospectus or free writing prospectus is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed materially since those dates. This prospectus supplement does not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in this prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that Unless the information appearing context otherwise indicates, references in this prospectus supplement, the documents accompanying prospectus and the information incorporated by reference herein and any related free writing prospectus is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed materially since those dates. You should also read and consider the information in the documents to which we have referred you in the sections entitled “Where You Can Find More Information” and “Incorporation by Reference” in this prospectus supplement. Unless otherwise indicated or the context otherwise requires, all references in this prospectus supplement therein to “InflaRx N.V.Edgewise Therapeutics, Inc.,” “InflaRx,” the “CompanyEdgewise,” “we,” “our,” “ours,” and “us” or similar terms refer refer, collectively, to InflaRx N.V. and its subsidiariesEdgewise Therapeutics, Inc., a Delaware corporation.

ABOUT THIS PROSPECTUS SUPPLEMENT. This document consists of two parts. The first part is this prospectus supplement, which describes the specific terms of this offering. The second part is the accompanying prospectus, which supplement is part of a registration statement that we have filed with the SEC using U.S. Securities and Exchange Commission, or the SEC, utilizing a “shelf” registration process. The accompanying prospectus describes more general information, some of which may not apply to this offering. Under this By using a shelf registration processstatement, we may from time to time sell offer shares of our common shares stock having an aggregate offering price of up to $50,000,000 50 million from time to time under this prospectus supplement at prices and on terms to be determined by market conditions at the time of the offering. Before buying any We provide information to you about this offering of our common stock in two separate documents that are bound together: (1) this prospectus supplement, which describes the common shares that specific details regarding this offering; and (2) the accompanying base prospectus, which provides general information, some of which may not apply to this offering. Generally, when we refer to this “prospectus supplement,” we are offering, we urge you referring to carefully read both documents combined. If information in this prospectus supplement and is inconsistent with the accompanying prospectus together with all of the information incorporated by reference hereinbase prospectus, as well as the additional information described under the headings “Where You Can Find More Information” and “Incorporation by Reference.” These documents contain important information that you should consider when making your investment decisionrely on this prospectus supplement. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in any document incorporated by reference in this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement, provided that if . If any statement in one of these documents is inconsistent with a statement in another document having a later date date—for example, a document incorporated by reference in this prospectus supplement—the statement in the document having the later date modifies or supersedes the earlier statement. We have not authorized anyone to provide any information other than that contained in or incorporated by reference in this prospectus and any related free writing prospectus filed by us with the SEC. We have not, and SVB Leerink has the Agents have not, authorized anyone to provide you with different informationinformation other than that contained in this prospectus supplement, the accompanying base prospectus and any free writing prospectus. We take no responsibility forare not, and can provide no assurance as to the reliability of any other information that others may give you. This prospectus supplement does not constitute Agents are not, making an offer to sell or the solicitation of an soliciting any offer to buy any securities other than the securities described in this prospectus supplement or an offer to sell or the solicitation of an offer to buy such these securities in any circumstances jurisdiction where the offer or sale is not permitted or in which such the person making that offer or solicitation is unlawfulnot qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. You should assume that the information appearing in this prospectus supplement, the accompanying base prospectus, the documents incorporated by reference herein and therein and any related free writing prospectus that we have authorized for use in connection with this offering is accurate only as of their the date of those respective datesdocuments. Our business, financial condition, results of operations and prospects may have changed materially since those dates. You should also read this prospectus supplement, the accompanying base prospectus, the documents incorporated by reference herein and consider therein and any free writing prospectus that we have authorized for use in connection with this offering in their entirety before making an investment decision. Before buying any of the common stock that we are offering, we urge you to carefully read this prospectus supplement, the accompanying base prospectus and all of the information in incorporated by reference herein and therein, as well as the documents to which we have referred you in additional information described under the sections entitled heading “Where You Can Find More Information” and “; Incorporation by Reference.” These documents contain important information that you should consider when making your investment decision. We are offering to sell, and seeking offers to buy, shares of common stock only in this prospectus supplementjurisdictions where offers and sales are permitted. Unless otherwise indicated or the context otherwise requires, all references in The distribution of this prospectus supplement and the offering of the common stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement must inform themselves about, and observe any restrictions relating to, the offering of the common stock and the distribution of this prospectus supplement outside the United States. This prospectus supplement does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. When we refer to “InflaRx N.V.Cerecor,” “InflaRx,” the “Company,” “we,” “our,” “ours,” and “us” in this prospectus supplement, we mean Cerecor Inc. or similar terms its consolidated subsidiaries, unless otherwise specified. When we refer to InflaRx N.V. “you,” we mean the holders of the applicable series of securities. This prospectus supplement includes our trademarks and trade names, including, without limitation, CERECOR and our logo, which are our property and are protected under applicable intellectual property laws. This prospectus supplement also contains trademarks, trade names and service marks of other companies, which are the property of their respective owners. Solely for convenience, trademarks, trade names and service marks referred to in this prospectus supplement may appear without the ®, ™ or SM symbols, but such references are not intended to indicate, in any way, that we or the applicable owner will not assert, to the fullest extent permitted under applicable law, our or its subsidiariesrights or the right of any applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other parties’ trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.

ABOUT THIS PROSPECTUS SUPPLEMENT. This document consists prospectus supplement and the accompanying base prospectus are part of two partsa “shelf” registration statement on Form S-3 (File No. The first part is this prospectus supplement333-236735) that we filed with the U.S. Securities and Exchange Commission, or the “SEC,” on February 28, 2020, which was amended on March 13, 2020 and declared effective on March 19, 2020. This prospectus supplement describes the specific terms of this offering. The second part is offering and also adds to and updates information contained in the accompanying prospectus, which is part of a registration statement that we filed with base prospectus and the SEC using a “shelf” registration process. The accompanying prospectus describes more general information, some of which may not apply to this offering. Under this shelf registration process, we may from time to time sell our common shares having an aggregate offering price of up to $50,000,000 under this prospectus supplement at prices and on terms to be determined documents incorporated by market conditions at the time of the offering. Before buying any of the common shares that we are offering, we urge you to carefully read both reference into this prospectus supplement and the accompanying prospectus together with all of base prospectus. The accompanying base prospectus, including the information documents incorporated by reference hereinreference, as well as the additional information described under the headings “Where You Can Find More Information” and “Incorporation by Reference.” These documents contain important information that you should consider when making your investment decisionprovides more general information. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying base prospectus or in any document incorporated by reference in that was filed with the SEC before the date of this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement, provided that if . If any statement in one of these documents is inconsistent with a statement in another document having a later date —— for example, a document incorporated by reference in this the accompanying base prospectus supplement—— the statement in the document having the later date modifies or supersedes the earlier statement. You should read this prospectus supplement and the accompanying base prospectus, including the information incorporated by reference and any free writing prospectus that we have authorized for use in connection with this offering, in their entirety before making an investment decision. You should rely only on the information contained or incorporated by reference in this prospectus supplement and the accompanying base prospectus, along with the information contained in any free writing prospectus that we have authorized for use in connection with this offering. We have not authorized anyone to provide any information other than that contained in or incorporated by reference in this prospectus and any related free writing prospectus filed by us with the SEC. We have not, and SVB Leerink has not, authorized anyone to provide you with different or additional information. We take no responsibility for, and can provide no assurance as to the reliability of any other information that others may give you. This prospectus supplement does not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in this prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus supplement, the accompanying base prospectus, the documents incorporated by reference in this prospectus supplement and the accompanying base prospectus, and in any related free writing prospectus that we have authorized for use in connection with this offering is accurate only as of their the respective datesdates of those documents. Our business, financial condition, results of operations and prospects may have changed materially since those dates. You should also read We further note that the representations, warranties and consider the information covenants made by us in the documents any agreement that is filed as an exhibit to which we have referred you in the sections entitled “Where You Can Find More Information” and “Incorporation any document that is incorporated by Reference” reference in this prospectus supplementsupplement or the accompanying base prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties and covenants were accurate only as of the date when made; therefore, such representations, warranties and covenants should not be relied on as accurate representations of the current state of our affairs. Unless otherwise we have indicated otherwise, or the context otherwise requires, all references in this prospectus supplement and the accompanying base prospectus to “InflaRx N.V.,” “InflaRxiBio,” the “Company,” “we,” “our,” “ours,” “us” or similar terms and “our” refer to InflaRx N.V. iBio, Inc. and its subsidiaries. This prospectus supplement, the accompanying base prospectus and the information incorporated by reference includes trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included or incorporated by reference into this prospectus supplement or the accompanying base prospectus are the property of their respective owners. We are offering to sell, and are seeking offers to buy, the common stock only in jurisdictions where such offers and sales are permitted. No action has been or will be taken in any jurisdiction by us or the sales agent that would permit a public offering of the common stock or the possession or distribution of this prospectus supplement and the accompanying base prospectus in any jurisdiction, other than in the United States. Persons outside the United States who come into possession of this prospectus supplement and the accompanying base prospectus must inform themselves about, and observe any restrictions relating to, the offering of the common stock and the distribution of this prospectus supplement and the accompanying base prospectus outside the United States. This prospectus supplement and the accompanying base prospectus do not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement and the accompanying base prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation.

ABOUT THIS PROSPECTUS SUPPLEMENT. This document consists of is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offeringoffering and the securities offered hereby, and also adds to and updates information contained in the accompanying prospectus and the documents incorporated into each by reference. The second part is the accompanying prospectus, which is part of a registration statement that we filed with the SEC using a “shelf” registration process. The accompanying prospectus describes provides more general information, some of which may not apply to this offering of common stock. This prospectus supplement is deemed to be incorporated by reference into the accompanying prospectus solely for the purpose of this offering. Under this shelf registration process, When we may from time refer only to time sell our common shares having the “prospectus,” we are referring to both parts combined. If there is an aggregate offering price of up to $50,000,000 under inconsistency between information in this prospectus supplement at prices and the accompanying prospectus, you should rely on terms the information in this prospectus supplement. You should rely only on the information contained in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein or therein. We have not authorized any other person to be determined by market conditions at provide you with different or additional information. If anyone provides you with different or additional information, you should not rely on it. This prospectus supplement and the time accompanying prospectus do not constitute an offer to sell or a solicitation of an offer to buy any securities other than the registered securities to which they relate, and this prospectus supplement and the accompanying prospectus do not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction where, or to any person to whom, it is unlawful to make such an offer or solicitation. You should not assume that the information contained in this prospectus supplement and the accompanying prospectus is correct on any date after the respective dates of the offeringprospectus supplement and the accompanying prospectus, as applicable, even though this prospectus supplement and the accompanying prospectus are delivered or securities are sold pursuant to the prospectus and such prospectus supplement or supplements at a later date. Before buying any You should assume that the information appearing in this prospectus supplement, the accompanying prospectus and the documents incorporated into each by reference is accurate only as of the common shares that we are offeringrespective dates of the applicable documents. Our business, we urge you to carefully financial condition, results of operations and prospects may have changed since those dates. You should read both this prospectus supplement and the accompanying prospectus together with all of the information incorporated by reference herein, as well as the additional information described under the headings “Where You Can Find More Information” and “Incorporation by Reference.” These documents contain important information that you should consider when making your investment decision. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in any document incorporated by reference in this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement, provided that if any statement in one of these documents is inconsistent with a statement in another document having a later date —for example, a document incorporated by reference in this prospectus supplement—the statement in the document having the later date modifies or supersedes the earlier statement. We have not authorized anyone to provide any information other than that contained in or incorporated by reference in this prospectus and any related free writing prospectus filed by us with the SEC. We have not, and SVB Leerink has not, authorized anyone to provide you with different information. We take no responsibility for, and can provide no assurance as to the reliability of any other information that others may give you. This prospectus supplement does not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in this prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus supplement, the documents incorporated by reference and any related free writing prospectus is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed materially since those dates. You should also read and consider the information in the documents to which we have referred you in the sections entitled “Where You Can Find More Information” and “Incorporation Certain Information by Reference” before investing in this prospectus supplementour common stock. Unless otherwise indicated or the context otherwise requiresrequires otherwise, all references in this prospectus supplement to “InflaRx N.V.,” “InflaRxGameStop,” the “Company,” “we,” “ourus,” “oursour” or comparable terms are to GameStop Corp., a Delaware corporation, and its consolidated subsidiaries. The distribution of this prospectus supplement, the accompanying prospectus and any authorized “free writing prospectus” and the offering of the shares of our common stock may be restricted by law. If you possess this prospectus supplement, the accompanying prospectus or any authorized “free writing prospectus,” you should find out about and observe these restrictions. This prospectus supplement, the accompanying prospectus and any authorized “usfree writing prospectus” are not an offer to sell the shares and are not soliciting an offer to buy the shares in any jurisdiction where the offer or similar terms refer sale is not permitted or where the person making the offer or sale is not qualified to InflaRx N.V. and its subsidiariesdo so or to any person to whom it is not permitted to make such offer or sale.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement and the accompanying prospectus form a part of a registration statement on Form S- 3 that we filed with the Securities and Exchange Commission, or SEC, using a “shelf” registration process under the Securities Act of 1933, as amended, or the Securities Act. This document consists of is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offering. The second part is offering of common stock and also adds to and updates information contained in the accompanying prospectus, which is part of a registration statement that we filed with prospectus and the SEC using a “shelf” registration process. The accompanying prospectus describes more general information, some of which may not apply to this offering. Under this shelf registration process, we may from time to time sell our common shares having an aggregate offering price of up to $50,000,000 under this prospectus supplement at prices and on terms to be determined documents incorporated by market conditions at the time of the offering. Before buying any of the common shares that we are offering, we urge you to carefully read both reference into this prospectus supplement and the accompanying prospectus together with all of prospectus. The second part, the information accompanying prospectus, including the documents incorporated by reference hereintherein, as well as the additional information described under the headings “Where You Can Find More Information” and “Incorporation by Reference.” These documents contain important information that you should consider provides more general information. Generally, when making your investment decisionwe refer to this prospectus, we are referring to both parts of this document combined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in any document incorporated by reference in that was filed with the SEC before the date of this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement, provided that if . If any statement in one of these documents is inconsistent with a statement in another document having a later date date—for example, a document incorporated by reference in this prospectus supplementsupplement or the accompanying prospectus—the statement in the document having the later date modifies or supersedes the earlier statement. We have not not, and JonesTrading has not, authorized anyone to provide any you with information other different than that or inconsistent with the information contained in or incorporated by reference in this prospectus supplement, the accompanying prospectus and in any related free writing prospectus filed by us that we have authorized for use in connection with the SECthis offering. We have not, and SVB Leerink has not, authorized anyone to provide you with different information. We JonesTrading take no responsibility for, and can provide no assurance as to the reliability of of, any other information that others may give you. This prospectus supplement does not constitute We are not, and JonesTrading is not, making an offer to sell or the solicitation of an offer to buy any securities other than the securities described in this prospectus supplement or an offer to sell or the solicitation of an offer to buy such these securities in any circumstances in which such jurisdiction where the offer or solicitation sale is unlawfulnot permitted. You should assume that the information appearing in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference in this prospectus supplement and the accompanying prospectus, and in any related free writing prospectus that we have authorized for use in connection with this offering, is accurate only as of their the date of those respective datesdocuments, regardless of the time of delivery of those respective documents. Our business, financial condition, results of operations and prospects may have changed materially since those dates. You should read this prospectus supplement, the accompanying prospectus, the documents incorporated by reference into this prospectus supplement and the accompanying prospectus, and any free writing prospectus that we have authorized for use in connection with this offering, in their entirety before making an investment decision. You should also read and consider the information in the documents to which we have referred you in the sections of this prospectus supplement entitled “Where You Can Find More Information” and “Incorporation of Certain Information by Reference.” We are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplementsupplement and the accompanying prospectus and the offering of our common stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement and the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering of our common stock and the distribution of this prospectus supplement and the accompanying prospectus outside the United States. This prospectus supplement and the accompanying prospectus do not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. Unless otherwise indicated or the context otherwise requiresindicates otherwise, all references as used in this prospectus supplement to and the accompanying prospectus, the terms “InflaRx N.V.Ocuphire,” “InflaRx,” the “Company,” “we,” “our,” “ours,” “us” or similar terms and “our” refer to InflaRx N.V. Ocuphire Pharma, Inc., a Delaware corporation, and its subsidiarieswholly-owned subsidiary on a consolidated basis. This prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein contain references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein, including logos, artwork and other visual displays, may appear without the ® or TM symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent permitted under applicable law, their rights thereto. We do not intend our use or display of other companies’ trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

ABOUT THIS PROSPECTUS SUPPLEMENT. This document consists of is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offeringoffering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. The second part is part, the accompanying prospectus, which is part of a registration statement that we filed with the SEC using a “shelf” registration process. The accompanying prospectus describes gives more general informationinformation about securities we may offer from time to time, some of which may does not apply to this offering. Under Generally, when we refer to this shelf registration processprospectus, we may from time are referring to time sell our common shares having an aggregate offering price both parts of up to $50,000,000 under this prospectus supplement at prices and on terms to be determined document combined together with all documents incorporated by market conditions at reference. If the time description of the offering. Before buying any of the common shares that we are offering, we urge you to carefully read both offering varies between this prospectus supplement and the accompanying prospectus together with all of the information incorporated by reference hereinprospectus, as well as the additional information described under the headings “Where You Can Find More Information” and “Incorporation by Reference.” These documents contain important information that you should consider when making your investment decision. To the extent there is a conflict between rely on the information contained in this prospectus supplement. However, on the one hand, and the information contained in the accompanying prospectus or in any document incorporated by reference in this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement, provided that if any statement in one of these documents is inconsistent with a statement in another document having a later date —— for example, a document incorporated by reference in into this prospectus supplement—supplement or the accompanying prospectus — the statement in the document having the later date modifies or supersedes the earlier statement. We have not authorized anyone to provide any You should rely only on the information other than that contained in or incorporated by reference in into this prospectus and any related free writing supplement or contained in or incorporated by reference into the accompanying prospectus filed by us with the SECto which we have referred you. We Neither we nor ACM have not, and SVB Leerink has not, authorized anyone to provide you with information that is different. If anyone provides you with different or inconsistent information, you should not rely on it. We do not, and ACM does not, take no responsibility for, and can provide no assurance assurances as to to, the reliability of any other information that others may give provide you. This prospectus supplement does not constitute an offer to sell The information contained in, or the solicitation of an offer to buy any securities other than the securities described in incorporated by reference into, this prospectus supplement and contained in, or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus supplement, the documents incorporated by reference and any related free writing into, the accompanying prospectus is accurate only as of their the respective datesdates thereof, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or of any sale of securities. Our businessIt is important for you to read and consider all information contained in this prospectus supplement and the accompanying prospectus, financial conditionincluding the documents incorporated by reference herein and therein, results of operations and prospects may have changed materially since those datesin making your investment decision. You should also read and consider the information in the documents to which we have referred you in under the sections entitled captions “Where You Can Find More Information” and “Incorporation of Documents by Reference” in this prospectus supplement and in the accompanying prospectus. We are offering to sell, and are seeking offers to buy, the shares only in jurisdictions where such offers and sales are permitted. The distribution of this prospectus supplement and the accompanying prospectus and the offering of the shares in certain jurisdictions or to certain persons within such jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement and the accompanying prospectus must inform themselves about and observe any restrictions relating to the offering of the shares and the distribution of this prospectus supplement and the accompanying prospectus outside the United States. This prospectus supplement and the accompanying prospectus do not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. We own or have rights to various trademarks, service marks and trade names that we use in connection with the operation of our business. This prospectus supplement, the accompanying prospectus and the information incorporated herein and thereby by reference may also contain trademarks, service marks and trade names of third parties, which are the property of their respective owners. Unless otherwise indicated Our use or the context otherwise requiresdisplay of third parties’ trademarks, all references service marks, trade names or products in this prospectus supplement or the accompanying prospectus is not intended to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks, service marks and trade names referred to in this prospectus may appear without the ®, TM or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, service marks and trade names. Unless otherwise stated or the context requires otherwise, references to “InflaRx N.V.,” “InflaRxBitNile,” the “Company,” “we,” “our,” “ours,” “us” or similar terms refer “our” are to InflaRx N.V. BitNile Holdings, Inc. (formerly Xxxx Global Holdings, Inc.), a Delaware corporation, and its subsidiaries.

ABOUT THIS PROSPECTUS SUPPLEMENT. This document consists of two parts. The first part is this prospectus supplement, which describes the specific terms of this offering. The second part is supplement and the accompanying prospectus, which is base prospectus are part of a registration statement that we have filed with the SEC using U.S. Securities and Exchange Commission, or the SEC, utilizing a “shelf” registration process. The By using a shelf registration statement, we may offer shares of our common stock having an aggregate offering price of up to $20,000,000 from time to time under this prospectus supplement and the accompanying prospectus describes pursuant to the Sales Agreement between the Company and Maxim. We provide information to you about this offering in two separate documents that are bound together. The first part consists of this prospectus supplement, which provides you with specific information about this offering. The second part, the accompanying base prospectus, provides more general information, some of which may not apply to this offering. Under this shelf registration processGenerally, when we may from time refer only to time sell our common shares having an aggregate offering price of up the “prospectus,” we are referring to $50,000,000 under this both documents combined. This prospectus supplement at prices and on terms to be determined by market conditions at the time of the offering. Before buying any of the common shares that we are offeringmay add, we urge you to carefully read both this prospectus supplement and the accompanying prospectus together with all of the information incorporated by reference herein, as well as the additional information described under the headings “Where You Can Find More Information” and “Incorporation by Reference.” These documents contain important information that you should consider when making your investment decision. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the update or change information contained in the accompanying prospectus or in base prospectus. If any document incorporated by reference statement we make in this prospectus supplementsupplement is inconsistent with statements made in the accompanying base prospectus, on the other hand, you should rely on the information statements made in this prospectus supplementsupplement will be deemed to modify or supersede those made in the accompanying base prospectus. However, provided that if any statement in one of these documents is inconsistent with a statement in another document having a later date date—for example, a document incorporated by reference in this prospectus supplementsupplement and the accompanying prospectus —the statement in the document having the later date modifies or supersedes the earlier statementstatement as our business, financial condition, results of operations and prospects may have changed since the earlier dates. We and Maxim have not authorized anyone to provide you with any information or to make any representations other than that those contained in or incorporated by reference in this prospectus and supplement, the accompanying base prospectus or any related free writing prospectus filed prospectuses prepared by or on behalf of us with the SEC. We or to which we or Maxim have not, and SVB Leerink has not, authorized anyone to provide you with different informationreferred you. We take no responsibility for, and can provide no assurance as to the reliability of of, any other information that others may give you. This prospectus supplement does We and Maxim are not constitute making an offer to sell or the solicitation of soliciting an offer to buy any securities other than the securities described in this prospectus supplement or an offer to sell or the solicitation of an offer to buy such our securities in any circumstances in which such jurisdiction where an offer or solicitation is unlawfulnot authorized or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. You should assume that the information appearing in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference herein, and in any related free writing prospectus that we may authorize for use in connection with this offering, is accurate only as of their the date of those respective datesdocuments. Our business, financial condition, results of operations and prospects may have changed materially since those dates. You should read this prospectus supplement and the accompanying prospectus, the documents incorporated by reference herein and therein and any free writing prospectus that we may authorize for use in connection with this offering in their entirety before making an investment decision. You should also read and consider the information in the documents to which we have referred you in the sections entitled section of this prospectus supplement and the accompanying prospectus titled “Where You Can Find More Information; Incorporation By Reference.” The industry and “Incorporation market data and other statistical information contained in the documents we incorporate by Reference” reference are based on our own estimates, independent publications, government publications, reports by market research firms or other published independent sources, and, in this prospectus supplementeach case, are believed by us to be reasonable estimates. Unless otherwise indicated or Although we believe these sources are reliable, we have not independently verified the context otherwise requires, all references in this prospectus supplement information. When we refer to “InflaRx N.V.,” “InflaRx,” the “CompanyNuZee,” “we,” “our,” “ours,” “us” or similar terms refer to InflaRx N.V. and the “Company” in this prospectus supplement and the accompanying prospectus, we mean NuZee, Inc. and its subsidiariessubsidiaries on a consolidated basis, unless otherwise specified. This prospectus supplement and the accompanying prospectus may include trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included in this prospectus supplement and the accompanying prospectus are the property of their respective owners.

ABOUT THIS PROSPECTUS SUPPLEMENT. This document consists prospectus supplement and the accompanying prospectus relate to an offering of two partsour Common Stock. The first part is Before investing in our Common Stock offered by this prospectus supplement, which describes the specific terms of this offering. The second part is the accompanying prospectus, which is part of a registration statement that we filed with the SEC using a “shelf” registration process. The accompanying prospectus describes more general information, some of which may not apply to this offering. Under this shelf registration process, we may from time to time sell our common shares having an aggregate offering price of up to $50,000,000 under this prospectus supplement at prices and on terms to be determined by market conditions at the time of the offering. Before buying any of the common shares that we are offering, we urge you to carefully read both this prospectus supplement and the accompanying prospectus prospectus, together with all of the information incorporated by reference herein, as well as the additional information described under the headings “Where You Can Find More Information” and “Incorporation by Reference.” in this prospectus supplement. These documents contain important information that you should consider when making your investment decision. This document is in two parts. The first part is this prospectus supplement, which describes the terms of this offering and also adds to, updates and changes information contained in the accompanying prospectus and the documents incorporated by reference. The second part is the accompanying prospectus, which gives more general information. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and supplement differs from or conflicts with the information contained in the accompanying prospectus or in any document incorporated by reference in this prospectus supplementreference, on the other hand, you should rely on the information in this prospectus supplement, provided that if supplement will control. If any statement in one of these documents is inconsistent with a statement in another document having a later date —— for example, a document incorporated by reference in into this prospectus supplement—supplement or the accompanying prospectus — the statement in the document having the later date modifies or supersedes the earlier statement. We have In deciding whether or not authorized anyone to provide any invest in our Common Stock, you should rely only on the information other than that contained in in, or incorporated by reference in into, this prospectus supplement, the accompanying prospectus and any related free writing prospectus filed by us that we have authorized for use in connection with this offering. Neither we nor the SEC. We Agents have not, and SVB Leerink has not, authorized anyone to provide you with different informationinformation or to make any representation other than those contained in, or incorporated by reference into, this prospectus supplement, the accompanying prospectus and any related free writing prospectus. We take no responsibility forIf anyone provides you with different or inconsistent information or representation, and can provide no assurance as to the reliability of any other information that others may give youyou should not rely on them. This prospectus supplement does and the accompanying prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in this prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities our Common Stock in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus supplement, the documents incorporated by reference accompanying prospectus and any related free writing prospectus and the documents incorporated by reference is accurate only as of their respective dates, regardless of the time of delivery of this prospectus supplement, the accompanying prospectus or any related free writing prospectus or any sale of our Common Stock. Our business, financial condition, results of operations and prospects may have changed materially since those dates. You should also read We further note that the representations, warranties and consider the information covenants made by us in the documents any agreement that is filed as an exhibit to which we have referred you in the sections entitled “Where You Can Find More Information” and “Incorporation any document that is incorporated by Reference” in reference into this prospectus supplementsupplement or the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our business, financial condition, results of operations or prospects. Unless otherwise indicated or the context otherwise requiresrequires otherwise, all references in this prospectus supplement to “InflaRx N.V.,” “InflaRxTeraWulf,” the “Company,” the “Registrant,” “we,” “our,” “ours,” “us” or similar terms and “our” refer to InflaRx N.V. and TeraWulf Inc. together with its consolidated subsidiaries.

ABOUT THIS PROSPECTUS SUPPLEMENT. This document is part of the registration statement that we filed with the Securities and Exchange Commission (the “SEC”) using a “shelf” registration process and consists of two parts. The first part is this prospectus supplement, including the documents incorporated by reference, which describes the specific terms of this offering. The second part is part, the accompanying prospectus, which is part of a registration statement that we filed with including the SEC using a “shelf” registration process. The accompanying prospectus describes documents incorporated by reference, gives more general information, some of which may not apply to this offering. Under this shelf registration processGenerally, when we may from time refer to time sell the “prospectus,” we are referring to both parts combined. This prospectus relates to the offering of our common shares having an aggregate offering price of up to $50,000,000 under this prospectus supplement at prices and on terms to be determined by market conditions at the time of the offeringstock. Before buying any of the common shares stock that we are offering, we urge you to carefully read both this prospectus supplement and the accompanying prospectus prospectus, together with all of the information incorporated by reference herein, as well as the additional information described under the headings “Where You Can Find More Information” and “Incorporation by Reference.” in this prospectus, and any free writing prospectus or prospectus supplement that we have authorized for use in connection with this offering. These documents contain important information that you should consider when making your investment decision. To This prospectus describes the extent there is a conflict between terms of this offering of common stock and also adds to and updates information contained in the documents incorporated by reference into this prospectus. If the information contained in this prospectus supplement, on the one hand, and differs or varies from the information contained in the accompanying prospectus or in any document incorporated by reference in herein that was filed with the SEC before the date of this prospectus supplement, on the other handprospectus, you should rely on the information set forth in this prospectus supplement, provided that if prospectus. If any statement in one of these documents is inconsistent with a statement in another document having a later date —(for example, a subsequently filed document deemed incorporated by reference in this prospectus supplement—prospectus), the statement in the document having the later date modifies or supersedes the earlier statement. We have Any statement so modified or superseded will not authorized anyone be deemed, except as so modified or superseded, to provide any constitute a part of this prospectus. You should rely only on the information other than that contained in or incorporated by reference in this prospectus and any related free writing prospectus filed by us with the SECprospectus. We have not, and SVB Leerink the sales agent has not, authorized anyone to provide you with information that is in addition to or different informationfrom that contained or incorporated by reference in this prospectus or contained in any permitted free writing prospectuses we have authorized for use in connection with this offering. We and the sales agent take no responsibility for, and can provide no assurance as to the reliability of of, any other information that others may give youprovide. This prospectus supplement does not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described The information contained in this prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus supplement, and the documents incorporated by reference and any related free writing prospectus herein is accurate only as of their respective dates, regardless of the time of delivery of any such document or the time of any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed materially since those dates. You should also It is important for you to read and consider the all information contained or incorporated by reference in this prospectus in making your investment decision. You should read this prospectus, as well as the documents to which we have referred you in incorporated by reference herein, the sections entitled additional information described under the section titled “Where You Can Find More Information” and “Incorporation of Certain Documents by Reference” in this prospectus supplementand any free writing prospectus that we have authorized for use in connection with this offering, before investing in our common stock. We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in this prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. We use various trademarks and trade names in our business, including without limitation our corporate name and logo. All other trademarks or trade names referred to in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus may be referred to without the ® and ™ symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. This prospectus and the documents incorporated by reference herein also contain estimates, projections and other information concerning our industry, our business, and the markets for certain diseases, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise indicated expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. We are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where such offers and sales are permitted. The distribution of this prospectus and the offering of our common stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of our common stock and the distribution of this prospectus outside the United States. This prospectus does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. As used in this prospectus, unless the context otherwise requires, all references in this prospectus supplement to “InflaRx N.V.,” “InflaRx,” the “Companycompany,” “we,” “ourus,” and “ours,our” “us” or similar terms refer to InflaRx N.V. and its subsidiaries.Aptinyx Inc.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement and the accompanying prospectus are part of a registration statement that we filed with the U.S. Securities and Exchange Commission, or the SEC, utilizing a “shelf” registration process. This document consists of is in two parts. The first part is this prospectus supplement, which describes the specific terms of the offering of the common stock offered hereby and also adds to and updates the information contained in the accompanying prospectus and the documents incorporated by reference into this offeringprospectus supplement and the accompanying prospectus. The second part is the accompanying prospectusprospectus dated June 14, 2021 (included in our Registration Statement on Form S-3 (File No. 333-256632)), which is part of a registration statement that we filed with the SEC using a “shelf” registration process. The accompanying prospectus describes provides more general information, some of which may not apply to this offering. Under this shelf registration process, we offering and some of which may from time to time sell our common shares having an aggregate offering price of up to $50,000,000 under have been supplemented or superseded by information in this prospectus supplement at prices and on terms or documents incorporated or deemed to be determined incorporated by market conditions at the time of the offering. Before buying any of the common shares that we are offering, we urge you to carefully read both reference into this prospectus supplement and that we filed with the accompanying prospectus together with all SEC subsequent to the date of the information incorporated by reference herein, as well as the additional information described under the headings “Where You Can Find More Information” and “Incorporation by Reference.” These documents contain important information that you should consider when making your investment decisionprospectus. To the extent that there is a any conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in any document incorporated by reference in this prospectus supplementherein or therein, on the other hand, you should rely on the information in this prospectus supplement, provided that if any statement in one of these documents is inconsistent with a statement in another document having a later date —for example, a document incorporated by reference . You should rely only on the information contained in this prospectus supplement—the statement , contained in the document having the later date modifies accompanying prospectus or supersedes the earlier statementincorporated herein or therein by reference. We have not authorized anyone to provide any you with information other than that contained is different. We are offering to sell, and seeking offers to buy, the common stock offered hereby only in jurisdictions where offers and sales are permitted. The information contained, or incorporated by reference in this prospectus and any related free writing prospectus filed by us with the SEC. We have notreference, and SVB Leerink has not, authorized anyone to provide you with different information. We take no responsibility for, and can provide no assurance as to the reliability of any other information that others may give you. This prospectus supplement does not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in this prospectus supplement and contained, or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus supplement, the documents incorporated by reference and any related free writing reference, in the accompanying prospectus is accurate only as of their the respective datesdates thereof, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus, or of any sale of our shares of common stock. Our business, financial condition, results of operations and prospects may have changed materially since those dates. You should also It is important for you to read and consider all information contained in this prospectus supplement and the information in accompanying prospectus, including the documents to which we have referred you to in the sections section entitled “Where You Can Find More Additional Information” and “Incorporation of Certain Information by Reference” below. We own or have rights to trademarks, trade names, or service marks that we use in conjunction with the operation of our business. Each trademark, trade name or service mark of any other company appearing in this prospectus supplement. Unless otherwise indicated supplement or the context otherwise requiresaccompanying prospectus belongs to its holder. Use or display by us of other parties’ trademarks, all trade names or service marks is not intended to and does not imply a relationship with, or endorsement or sponsorship by us of, the trademark, trade name or service mark owner. All references in this prospectus supplement or the accompanying prospectus to “InflaRx N.V.,” “InflaRxTorchlight,” the “Company,” “we,” “ourus,” or “ours,our” “us” mean Torchlight Energy Resources, Inc. and our consolidated subsidiaries, unless we state otherwise or similar terms refer to InflaRx N.V. and its subsidiariesthe context indicates otherwise.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement is a supplement to the accompanying prospectus that is also a part of this document. This prospectus supplement and the accompanying prospectus, dated January 13, 2020, are part of a registration statement on Form S-3 (File No. 333-235791) that we filed with the Securities and Exchange Commission (the “SEC”), utilizing a “shelf” registration process. Under the shelf registration process, we may offer and sell from time to time in one or more offerings our Common Stock described in the accompanying prospectus. This document consists of is in two parts. The first part is this prospectus supplement, which describes our Common Stock we are offering and the specific terms of this offeringthe offering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into the accompanying prospectus. The second part is the accompanying prospectus, which is part of a registration statement that we filed with the SEC using a “shelf” registration process. The accompanying prospectus describes provides more general information. Generally, some of which may not apply when we refer to this offering. Under this shelf registration process, we may from time to time sell our common shares having an aggregate offering price of up to $50,000,000 under this prospectus supplement at prices and on terms to be determined by market conditions at the time of the offering. Before buying any of the common shares that “prospectus,” we are offering, we urge you referring to carefully read both this prospectus supplement and the accompanying prospectus together with all of the information incorporated by reference herein, as well as the additional information described under the headings “Where You Can Find More Information” and “Incorporation by Reference.” These documents contain important information that you should consider when making your investment decisioncombined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in any earlier dated document incorporated by reference in this prospectus supplementtherein, on the other hand, you should rely on the information in this prospectus supplement, provided . Additional prospectus supplements or documents filed after the date hereof that if any statement in one of these documents is inconsistent with a statement in another document having a later date —for example, a document are deemed incorporated by reference herein may modify and supersede the information in this prospectus supplement—the statement in the document having the later date modifies or supersedes the earlier statement. We urge you to carefully read this prospectus supplement and the accompanying prospectus and any related free writing prospectus, together with the information incorporated herein and therein by reference as described under the heading “Incorporation of Information by Reference,” before buying any of our Common Stock being offered. You should rely only on the information that we have not authorized anyone to provide any information other than that contained in provided or incorporated by reference in this prospectus supplement and the accompanying prospectus and any related free writing prospectus filed by us with the SECthat we may authorize to be provided to you. We have not, and SVB Leerink Agent has not, authorized anyone to provide you with different information. We take no responsibility forNo other dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus supplement and can provide no assurance as the accompanying prospectus or any related free writing prospectus that we may authorize to the reliability of be provided to you. You must not rely on any other unauthorized information that others may give youor representation. This prospectus supplement does not constitute is an offer to sell or the solicitation of an offer only our Common Stock offered hereby and only under circumstances and in jurisdictions where it is lawful to buy any securities other than the securities described in this prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawfuldo so. You should assume that the information appearing in this prospectus supplement, supplement and the documents incorporated by reference and accompanying prospectus or any related free writing prospectus is accurate only as of their respective datesthe date on the front of the document and that any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or any related free writing prospectus, or any sale of our Common Stock. Our business, financial condition, results This prospectus supplement contains summaries of operations and prospects may have changed materially since those dates. You should also read and consider the information certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which we have referred this prospectus supplement is a part, and you in may obtain copies of those documents as described below under the sections entitled heading “Where You Can Find More Information.” and “Incorporation by Reference” As used in this prospectus supplement, the terms “we”, “us”, “our”, “Company”, “Monopar Therapeutics” and “Monopar” refer to Monopar Therapeutics Inc., a Delaware corporation. Unless otherwise indicated We own or have rights to trademarks or trade names that we use in conjunction with the context otherwise requiresoperation of our business. Each trademark, all references trade name or service mark of any other company appearing in this prospectus supplement or the accompanying prospectus belongs to “InflaRx N.V.,” “InflaRx,” its holder. Use or display by us of other parties’ trademarks, trade names or service marks is not intended to and does not imply a relationship with, or endorsement or sponsorship by us of, the “Company,” “we,” “our,” “ours,” “us” trademark, trade name or similar terms refer to InflaRx N.V. and its subsidiariesservice mark owner.